Alpha Teknova’s 2026 Q2 Earnings Call: Biotech Revenue Timing and BuildTech Monetization Contradictions

<<>>

Date of Call: Aug 5, 2026

Financials Results

• Revenue: $12M, up 18% YOY, highest quarterly revenue in company history
• EPS: -$0.06 per diluted share, compared to -$0.07 per diluted share in the prior year
• Gross Margin: 40.1%, up from 38.7% in Q2 2025

Guidance:

• 2026 total revenue guidance raised to $45M-$47M (midpoint ~14% growth vs 2025).
• Expect gross margin for full year 2026 to be in the mid to upper 30s percentage range.
• Operating expenses forecast at least $8M per quarter through end of 2026.
• Expect to become adjusted EBITDA positive at annualized revenue of $52M-$57M.
• 2027 revenue target unchanged at low $50M range; potential upside if tailwinds materialize.
• Full year 2026 free cash outflow expected to be less than $8M.

Business Commentary:

Revenue Growth and Historical Performance:

• TechNova reported record revenue of over $12 million for Q2 2026, marking an 18% increase compared to Q2 2025.
• The growth was broad-based across major target segments, with the largest direct customer representing less than 7% of total revenue.

Biopharma and Cell & Gene Therapy Dynamics:

• Revenue from biopharma, including biotech, large pharma, and CDMOs, grew significantly, excluding cell and gene therapy-related accounts, which were down due to order timing.
• The muted performance in cell and gene therapy was attributed to softness in orders, although there is an expectation of future growth as therapies progress through clinical trials.

AI Integration and Custom Product Development:

• TechNova launched BuildPet, an AI-powered custom order configurator, to streamline the design and ordering of custom products.
• This tool is expected to reduce the time required for complex custom product design from weeks to a few days, enhancing customer engagement and efficiency.

Cash Flow and Financial Outlook:

• The company achieved its lowest free cash outflow since before its IPO, anticipating less than $8 million for the full year 2026 despite increased commercial investments.
• The improved cash flow was due to lower cash use in operating activities, supported by strong revenue performance.

Clinical Solutions and Customer Engagement:

• Clinical solutions revenue increased by 18% to $2.4 million, driven by an increased number of customers despite lower average revenue per customer.
• Growth in this segment is expected as customers ramp up purchase volumes as their therapies advance through clinical trial phases.

Sentiment Analysis:

Overall Tone: Positive

• Management expressed being 'very pleased' with performance, citing 'highest quarterly revenue in our 30-year history' and 'lowest free cash outflow since before our IPO.' They increased revenue guidance, highlighted 'strong' funnel and 'broad-based' growth, and noted AI tool BuildTech is 'only the beginning' with excitement for future evolution.

Q&A:

• Question from Brandon Smith (TD Conway): Can you speak more to visibility on the order funnel in Q3/Q4, dynamics in biopharma/CDMOs, and the timing of biotech funding impact?
  Response: The funnel looks strong but does not yet include the expected biotech funding roll-through, which is anticipated later; current guidance for H2 does not factor this in.

• Question from Brandon Smith (TD Conway): How should we think about monetization and impact of the BuildTech launch on revenue or optics?
  Response: BuildTech is not a paid tool; it's designed to increase brand strength, enable faster custom product design, and bring new customers into the custom product flow, with future online quoting planned.

• Question from Jacob Cranville (William Blair): How are you viewing expectations for 2027 and what needs to improve to achieve the low $50M revenue target?
  Response: The 2027 target at low $50M is unchanged and viewed as prudent; upside potential exists if biotech funding, commercial investments, and customer commercialization impacts materialize.

• Question from Jacob Cranville (William Blair): What are inter-quarter demand trends, month-over-month, and any risks of order push-outs?
  Response: Guidance assumes H2 revenue mirrors H1 (~$23M per half), with Q3 typically stronger than Q4 seasonally; no material risk of push-outs in cell and gene therapy, which is a smaller revenue segment.

• Question from Matt Hewitt (Greyhound Capital Group): Did you say low double-digit growth for all modalities, including cell and gene therapy?
  Response: No, the low double-digit growth comment referred specifically to the catalog business, not including cell and gene therapy.

• Question from Matt Hewitt (Greyhound Capital Group): What progression are you seeing in clinical trials (Phase I to III) and how many Phase III customers are you working with?
  Response: Later-stage customers are progressing as planned; the company had five customers in Phase II/III at end of 2025. Early-stage engagement has increased with higher quote intent, but biotech funding impact has not yet reached revenue.

• Question from Mark Massaro (BTIG): In liquid biopsy, what areas (early detection, MRD, etc.) are showing the biggest growth signs?
  Response: Growth is broad-based across liquid biopsy segments, including reagent sales and full GMP manufacturing, with engagement from companies in various applications like MRD and prenatal testing.

• Question from Mark Massaro (BTIG): What is driving the increase in average revenue per customer in LabEssentials?
  Response: Driven primarily by higher custom product orders, especially from spatial biology and liquid biopsy companies for research-use-only products, leading to larger order sizes.

• Question from Mark Massaro (BTIG): With $17M+ cash, are you still looking at inorganic growth opportunities? What are you targeting?
  Response: Yes, actively evaluating M&A to expand geographically or into complementary reagents (e.g., proteins), but the focus remains on organic path to cash flow positivity.

• Question from Matt Parisi (KeyBank Capital Markets): What is the GMP customer count trend in H1 2026?
  Response: GMP customer count increased, with new onboarding ongoing; average revenue per customer declined due to smaller initial orders but engagement and therapy progression are positive.

• Question from Matt Parisi (KeyBank Capital Markets): Any update on the Pluristics collaboration and expected revenue impact?
  Response: Collaboration is in early stages; no material revenue impact expected in near term as migration from research to therapeutic commercialization takes time.

• Question from Hannah (Stevens Inc.): Are there any other pockets of weakness besides cell and gene therapy? Any nuances in cgt weakness?
  Response: Cell and gene therapy was the only underperforming segment, partly due to order timing; weakness is more in early-stage R&D. Later-stage therapies continue to move forward and order.

• Question from Hannah (Stevens Inc.): Why did incremental margins trend lower than typical 70%?
  Response: Attributed to a tough comparison against Q2 2025, which had unusually favorable manufacturing efficiencies; underlying improvement was expected and masked by the prior-year comparison.

• Question from Max Masucci (Roth Capital Partners): How has BuildTech quote volume trended since launch, and could it shift catalog customers to custom?
  Response: BuildTech usage has increased; it is helping engage new customers and could become a growth tailwind by 2027 by differentiating Technova's custom offering.

• Question from Max Masucci (Roth Capital Partners): How are the new field reps and commercial investments performing? Expect benefit in new accounts, funnel conversion, or deal size?
  Response: Commercial investments are executing well, improving funnel with more meetings; benefits are expected to materialize in Q1 2027, impacting new account wins and complex deals.

• Question from Mark Massaro (BTIG): What is facility utilization and capacity outlook?
  Response: Utilization is low relative to $200M revenue target (currently ~4-5 days per week, one shift); ample capacity exists to ramp without additional facility build, focusing on efficiency and lean manufacturing.

• Question from Mark Massaro (BTIG): With commercial/Salesforce investments progressing, how does that inform future investment for 2027?
  Response: Will evaluate ROI likely by late Q3/early Q4; may consider further investment if needed for additional growth, but current $2M investment is showing nice growth.

Contradiction Point 1

Biotech Funding Impact and Revenue Timing

Contradiction on whether biotech funding tailwinds are already impacting revenue.

Brandon Smith (TD Conway) - Brandon Smith (TD Conway)

2026Q2: The new revenue guidance does not factor in the expected funding impact, which is anticipated later in 2026 or early 2027. - Stephen Gunstream(CEO)

Can you provide details on the order funnel for Q3 and Q4 in the biotech, pharma, and CDMOs segment, including the typical 3–4 quarter lag between funding and revenue, and the growth assumptions underlying the new H2 guidance? - Matt Hewitt (Greyhound Capital Group)

2026Q2: Growth is currently driven more by ongoing conversations and planning than by new funding. - Stephen Gunstream(CEO)

Contradiction Point 2

Commercial Investment ROI Timeline

Contradiction on when benefits from sales and lead generation investments will materialize.

Max Masucci (Roth Capital Partners) - Max Masucci (Roth Capital Partners)

2026Q2: The benefit is expected to materialize in Q1 2027, as it takes time for complex deals to close. - Stephen Gunstream(CEO)

How are the newly hired field reps with existing relationships impacting new account wins, funnel conversion, or deal size through commercial investments? - Mark Massaro (BTIG)

2026Q2: The company will evaluate further investment in late Q3/early Q4. The current $2M investment is showing positive growth... - Stephen Gunstream(CEO)

Contradiction Point 3

Customer Pipeline and Clinical Stage Progression

Statements about customer pipeline health and progression through clinical stages conflict between quarters.

Jacob Cranville (William Blair) - Jacob Cranville (William Blair)

2026Q2: The cell and gene therapy order push is small and poses no risk of further delays. The muted performance is more about timing and early-stage R&D softness, not large, late-stage orders. - Stephen Gunstream(CEO)

What were the inter-quarter demand trends exiting Q2, how confident are you that the pushed cell and gene therapy orders will materialize in Q3 without further delays, and what factors are embedded in the back-half guidance? - Brendan Smith (TD Cowen)

2026Q1: The goal is to onboard more clinical customers, and an improvement in biotech funding should support this trend. - Stephen Gunstream(CEO)

Contradiction Point 4

Impact of Commercial Investments on Revenue Timeline

The expected timeline for commercial investments to impact revenue is given as late 2026/early 2027, conflicting with a prior 6-12 month ramp period.

Jacob Cranville (William Blair) - Jacob Cranville (William Blair)

2026Q2: The benefit is expected to materialize in Q1 2027, as it takes time for complex deals to close. - Stephen Gunstream(CEO)

Regarding inter-quarter demand trends, what was the month-over-month performance exiting Q2, what confidence is there that the Q2-to-Q3 cell and gene therapy order push will materialize in Q3, and what risks of further delays exist, along with what is embedded in the back-half guidance? - Matthew Parisi (KeyBanc Capital Markets)

2026Q1: Typically 6-12 months before a significant impact is seen... Early indicators are positive... impact expected by end of 2026/early 2027. - Stephen Gunstream(CEO)

Contradiction Point 5

Monetization and Impact of BuildTech AI Configurator

Inconsistent characterization of the tool's business model and revenue contribution.

Brandon Smith (TD Conway) - Brandon Smith (TD Conway)

2026Q2: BuildTech is not a paid tool; it is designed to enhance customer engagement... The primary goal is to increase brand strength and bring new customers into the custom product business, not to generate direct revenue from its use. - Stephen Gunstream(CEO)

Is the BuildTech AI configurator monetized (e.g., customers pay to use it) and how should we think about its impact on revenue or financial optics? - Brendan Smith (TD Cowen)

20260227-2025 Q4: The investment includes... increasing branding/awareness efforts. A significant portion involves expanding private-label manufacturing for these customers. The strategy leverages... to transition into larger-volume production and private-label opportunities, driving revenue growth in 2026/2027. - Stephen Gunstream(CEO)

<<>>